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Introduction
Polycystic ovary syndrome (PCOS) is one the
most common reproductive endocrine diseases
affecting 5-7% of female population in reproduc-
tive age(1). PCOS is characterized by chronic
anovulation, excess androgen, and insulin resis-
tance. PCOS most often is accompanied by hyper-
tension, obesity, diabetes mellitus (DM) type II,
and insulin resistance(2). Females with PCOS may
be the largest female population with premature
atherosclerosis and cardiovascular diseases (CVD)
events(3, 4). However, according to a meta-analysis
performed in 2012(1), there is still controversy
whether the observed CVD risk factors in PCOS
patients really increase CVD events and subclinical
atherosclerosis in this population(1).
In early stages of atherosclerosis, carotid
artery intima media thickness (CIMT) increases. In
assessment of subclinical atherosclerosis, the most
important with least complications is to measure
CIMT. Prospective studies have demonstrated that
increased CIMT is a strong predictor for coronary
artery events and cerebrovascular diseases related
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ABSTRACT
Objective: To determine relationship between CRP (C-reactive protein) concentration and CIMT (carotid artery intima media
thickness) in young PCOS (polycystic ovary syndrome) females. 
Design: Cross-sectional
Setting: Infertility outpatient clinic
Patients: 70 PCOS patients (20-39 years old) and 70 healthy subjects as control. 
Interventions: CIMT was measured by Doppler ultrasound. 
Main outcome measure: Relationship between increased CRP level and CIMT. 
Results: Mean (±SD) serum CRP level was higher in PCOS patents (5.2 ± 2.8 mg/dL) in comparison to controls (4.9 ± 1.7
mg/dL), but the difference was not statistically significant (P= 0.482). However, mean (±SD) CIMT was significantly higher in PCOS
group (0.65 ± 0.11 mm) compared to controls (0.59 ± 0.21 mm); P= 0.016. Although with increased CRP level, CIMT increased in
PCOS patients, the relationship was not statistically significant (P= 0.065, r= 0.886). Also there was a relationship between age and
CIMT but it was not statistically significant (P= 0.07, r= 0.215). However, relationships between CIMT and BMI (P= 0.04, r= 0.571)
and between CIMT and waist circumference (P= 0.028, r= 0.36) were statistically significant. Based on regression analysis serum
CRP level (P= 0.055, 95% CI= 1.589-73.713) and BMI (P= 0.051, 95% CI= 1.379-2.412) were independent variables which affected
CIMT.       
Conclusion: CRP was elevated in PCOS patients compared to controls, but the difference was not statistically significant.
Therefore, measuring CRP in PCOS patients should be interpreted with keeping in mind other CVD risk factors in these patients such
as fasting blood sugar, lipid profile, and most importantly BMI.
Key words: Polycystic ovary syndrome (PCOS), carotid intima media thickness (CIMT), C-reactive protein (CRP); athero-
sclerosis.
to CVD risk factors including older age, dyslipi-
demia, and obesity(1). This state of increased CIMT
has also been implicated in PCOS patients in sev-
eral studies(5-7), though there is evidence that CIMT
was not higher in PCOS patients (whether in
hyperandrogenic or non-hyperandrogenic patients)
compared to matched Korean controls(5).  
Inflammation is a risk factor in progression of
atherosclerosis(8). In former studies it has been
shown that C-reactive protein (CRP), as a marker
for inflammation, predicts stroke, myocardial
infarction (MI), peripheral vascular diseases, and
sudden death(9). Although it seems that inflamma-
tion markers have more significant relationship
with onset of atherosclerosis compared to lipid
profile, the relationship between increased CRP
level and increased CIMT is still controversial,
though recent evidence suggests that there is a rela-
tionship(10, 11). In a study on PCOS patients, it was
reported that fasting CRP level was significantly
higher than control group(12).   
In this study, we intended to measure CIMT,
as an indicator of subclinical atherosclerosis, in
PCOS patients and determine its relationship with
serum CRP concentration. If a significant relation-
ship is found between high CRP level and
increased CIMT, atherosclerosis can be slowed
down via screening and monitoring this high risk
group by serum CRP level as well as appropriate
preventive measures including but not limited to
lifestyle modifications and even medical therapeu-
tic interventions.  
Materials and methods
Study population
In this cross-sectional study, 70 patients (20-
39 years old) with the diagnosis of PCOS accord-
ing to the Rotterdam criteria (to criteria were
required of 3 criteria to make the diagnosis of
PCOS) were included(13). These patients presented
to our tertiary infertility center. The sampling was
done via convenience method. The sample size
was determined according to the Cohen table
(alpha= 5%, B= 20%, power= 80%). Inclusion cri-
teria consisted of age range between 20 and 39
years old, no pre-existing medical condition, not
taking hormonal medications, body mass index
(BMI) between 18-30 kg/m2 (neither underweight,
nor obese persons), and not having metabolic syn-
drome(14) according to the definition by the 2001
National Cholesterol Education Program/ATP III
(defined as waist circumference > 88 cm, serum
triglyceride > 150 mg/dL, blood pressure > 130/85
mmHg, fasting plasma glucose > 100 mg/dL, and
serum HDL < 40 mg/dL). Control group consisted
of patients who presented to the infertility clinic,
but the cause of infertility was not PCOS. They
were matched with the PCOS group regarding age
and BMI. Exclusion criteria for both PCOS and
control groups were history of premature coronary
artery disease in the family, stroke, any vascular
disease, any chronic inflammatory condition (e.g.,
rheumatoid arthritis, systemic lupus erythematosus,
connective tissue diseases, chronic infection), and
cigarette smoking.  
Data gathered
A checklist containing the required data was
filled out for the patients. The data were age,
weight, height, waist circumference, buttock cir-
cumference, systolic and diastolic blood pressure,
history of previous diseases, and medication histo-
ry. Then, serum levels of total cholesterol, low den-
sity lipoprotein (LDL)-cholesterol, high density
lipoprotein (HDL)-cholesterol, FSH (follicle stim-
ulating hormone), LH (luteinizing hormone), pro-
lactin, testosterone, fasting blood glucose (FBS),
and CRP were measured by the hospital’s laborato-
ry. CRP was measured by Cobas Integra® via bio-
chemical analysis. All CRP measurements were
done in a single laboratory. Normal range was less
than 5 mg/dL.    
CIMT measurement
To measure CIMT, the patients underwent
Doppler ultrasound using B-mode method by a
board-certified radiologist at our hospital. Doppler
ultrasound of both common carotid arteries was
done and at the best point, the distance between
intima and media was measured. Mean of the two
measurements on both sides made for each patient
was regarded as CIMT for that particular patient. 
Statistical analyses
These were accomplished by the SPSS soft-
ware for Windows (ver. 16.0). To express data,
descriptive indices such as frequency, percentage,
mean, and standard deviation (SD) were used. To
compare the categorical variables between PCOS
and control groups, the Chi-squared test was done
and for continuous variables the student t-test was
done. 
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Ethics
The study proposal was first prepared and
submitted to the Ethics Committee of Tehran
University of Medical Sciences and after getting
approval from this committee the study was initiat-
ed. The study protocol was in conformity with the
ethical guidelines of the 1975 Declaration of
Helsinki(15).
Results
Mean (±SD) ages of PCOS and control
groups were 28.9 (±2.8) and 27.9 (±2.7) years,
respectively (P = 0.104). Table 1 presents BMI,
waist circumference, hip circumference, and sys-
tolic and diastolic blood pressure measurements in
the two groups. As expected, both systolic blood
pressure and diastolic blood pressure were signifi-
cantly higher in PCOS patients. 
Regarding laboratory findings, FBG, triglyc-
eride, and total cholesterol were higher significant-
ly in PCOS group (Table 2). All three hormones
measured here including FSH, LH, and testos-
terone levels were significantly higher in the
patients compared to controls (Table 3). 
Mean (±SD) serum CRP level was higher in
PCOS patients (5.2 ± 2.8 mg/dL) in comparison to
controls (4.9 ± 1.7 mg/dL), but the difference was
not statistically significant (P= 0.482).
However, mean (±SD) CIMT was significant-
ly higher in PCOS group (0.65 ± 0.11 mm) com-
pared to controls (0.59 ± 0.21 mm); P= 0.016. 
According to correlation analysis, no signifi-
cant relationship was detected between serum CRP
level and CIMT, however with increased CRP
level, CIMT also showed an increased pattern (P=
0.065, r= 0.886). Also there was a relationship
between age and CIMT but it was not statistically
significant (P= 0.07, r= 0.215). However, relation-
ships between CIMT and BMI (P= 0.04, r= 0.571)
and between CIMT and waist circumference (P=
0.028, r= 0.36) were statistically significant.      
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Table 1: Comparison of mean (±SD) BMI, waist and but-
tock circumferences, and blood pressure between polycy-
stic ovary syndrome (PCOS) patients and controls.
Table 2: Comparison of mean (SD) lipid profile and
fasting blood glucose between PCOS and control groups.
Table 3: Comparison of mean (SD) serum FSH, LH, and
testosterone levels between PCOS patients and controls.
Table 4: Comparison of the studied variables between
normal CIMT (< 0.6 mm) and increased CIMT (> 0.6
mm) in PCOS patients.
Table 5: Regression analysis of the studied variables and
carotid artery intima media thickness in PCOS patients.
Based on CIMT, the PCOS patients were
divided into two groups of normal CIMT (< 0.6
mm) and increased CIMT (> 0.6 mm). Table 4
depicts comparison of the studied variables
between normal and increased CIMT in PCOS
patients. As shown, no significant difference in
terms of studied variables was observed between
normal and increased CIMT groups in PCOS
patients.
Regression analysis showed that serum CRP
level and BMI were independent variables which
affected CIMT (Table 5).     
Conclusion
The results of the present study indicated that
plants can remove contaminants. In the present
study, matricaria chamomilla could remove TPH at
a maximum rate of 49.73 and 51.97% % in concen-
tration of .25 for light and heavy types of petrole-
um, respectively. Concentration of 4% was the crit-
ical concentration for matricaria chamomilla in
both types of petroleum because in this concentra-
tion the plant cannot grow and the microbial popu-
lation was lower compared to other contamination
concentrations. Nonionic surfactant Tween 80 had
a better performance in regard with removal per-
centage of TPH and an increase in microbial popu-
lation compared to anionic surfactant and the treat-
ment without surfactant in both types of petroleum.
Discussion
Recent studies suggest that CDV risk factors
are increased in PCOS patients(1). Evidence sug-
gests that coronary artery disease and stroke are
two times more likely to occur in PCOS patients a
recent meta-analysis showed women with PCOS(16,
17). CIMT has been used in several studies in PCOS
patients in order to demonstrate subclinical athero-
sclerosis. There is inconsistency between the stud-
ies about the exact role of CIMT and comparable
to the current results, they showed significantly
increased CIMT in PCOS patients which is indica-
tive of subclinical atherosclerosis(4, 6). Although
there is inconsistency in related studies, but a
meta-analysis of 19 articles performed by Meyer et
al.(1) showed that mean difference in CIMT among
women with PCOS compared with controls was
0.072 mm (95% CI, 0.040-0.105; P < 0.0001) for
highest quality studies, and 0.084 mm (95% CI,
0.042-0.126; P < 0.0001) for good quality studies(5).
However, some studies did not find any difference
between PCOS and controls. For example, Kim et
al.(5) did not find any difference in terms of CIMT
between Korean PCOS and age-matched controls.
In their study on 56 PCOS cases and 56 controls, 
Mean (SD) CIMT in cases and control groups
were 0.49 (± 0.09) mm and 0.50 (± 0.11), respec-
tively; P= 0.562. Several factors can explain incon-
sistency between studies. Considering the complex
nature of PCOS, age, BMI, low sample size, the
method of CIMT measurement, and so forth are the
possible causes of this controversy. Mean values
for BMI and age of PCOS cases in Korean study
were 21.2 kg/m2 and 30.9 years, whilst these fig-
ures in our study were 25.4 kg/m2 and 28.9 years.
We decided to include PCOS patients with BMI
ranging from 18-30, and as expected mean BMI
value of the recruited cases was high, which we
think is more representative of PCOS patients rou-
tinely visited in our clinic.
Serum CRP level is an established inflamma-
tory marker, and as stated previously, is a potential
predictor for CVD and stroke(9). By measuring this
marker in PCOS cases and comparing it with con-
trols, we intended to find whether this marker can
be used as an easy and accessible rapid way to
assess CVD in such patients. The results obtained
showed that this marker, although was higher in
PCOS compared to control group, the difference
was not statistically significant. 
Increased CRP levels in PCOS patients has
been reported earlier(18, 19). Cascella et al.(12) who
noted significant increase in mean CRP level in
PCOS patients (1.9 mg/L) vs. controls (0.8 mg/L).
They also reported that CRP positively affected
CIMT. They also found increased levels of other
inflammatory markers including fibrinogen, white
blood cell count, and plasminogen-activated
inhibitor-1 levels in PCOS compared to controls.
In the latter mentioned study, mean BMI value of
PCOS patients was 28.5 which is higher than BMI
of our patients. However, this is in consistent with
Kim et al. study(5) who reported median (range) of
highly sensitive C-reactive protein (hs-CRP) in
PCOS and control group as  0.01 (0.01-1.15) and
0.02 (0.01-0.29) mg/dL, respectively; P= 0.28. 
The role of weight and its relationship with
CRP level should be considered here. Considering
several factors contribute to CRP level such as
obesity, hypertension, dyslipidemia, it may be stat-
ed that the factor or factors which determine CRP
level in PCOS patients are different in this popula-
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tion, and therefore this variation of contributing
factors adjust various results regarding CRP.
Mohlig et al.(20) noted that serum CRP level in
PCOS patients is related to weight (i.e., obesity)
rather than PCOS per se. In their study on 57
PCOS patients with a control group, they reported
that neither CRP nor IL-6 were significantly ele-
vated in lean or obese PCOS patients compared
with age-matched lean or obese controls. But BMI
itself, not PCOS, was the main factor related to
elevated CRP and chronic inflammation. The two
groups studied here had no difference regarding
BMI. This is in agreement with Mohlig et al.
study(20) considering the role of BMI and weight
excess in chronic inflammation. These findings are
in agreement with another study by Oh et al.(21).
Their study included 30 lean (BMI< 23 kg/m2)
PCOS patients and a control group. They noted
that even though serum hs-CRP levels were higher
in lean women with PCOS (mean (SD)=
0.72±0.20) than in control group (mean(SD)=
0.27±0.04 mg/L), the difference was no longer sig-
nificant after adjusting for BMI. According to their
multiple regression analysis, BMI, systolic blood
pressure, and insulin-mediated glucose uptake
were predicting factors for CRP. In other words,
established CVD risk factors which are present
more frequently in PCOS patients than control sub-
jects are the determining factors in CRP level. We
also observed a significant difference with respect
to fasting blood glucose, HDL, triglyceride, and
total cholesterol between PCOS and control
groups, but not LDL concentration. About CIMT,
neither CRP nor other CVD risk factors were dif-
ferent between normal and elevated CIMT.      
In conclusion, CRP was elevated in PCOS
patients compared to controls, but the difference
was not statistically significant. Therefore, measur-
ing CRP in PCOS patients should be interpreted
with keeping in mind other CVD risk factors in
these patients such as fasting blood sugar, lipid
profile, and most importantly BMI. 
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